Ocean Biomedical Inc (OCEA) Actualités

Form 8-K - Current report

Updated: Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with Polar Multi-Strategy Master Fund

Providence, RI, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announces that the...

Ocean Biomedical Announces Loan Commitment from Largest Stockholder; Up to $10 Million

Providence, RI, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that...

Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with a Key Financing Partner

Providence, RI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that...

Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers

Company to Host Cancer R&D Update on October 19, 2023 to Share Latest Details of Multipronged Cancer...

Ocean Biomedical (NASDAQ: OCEA) Will Host an R&D Update Today on Malaria, and Fibrosis Programs with Scientific Co-founders Jack A. Elias, MD, and Jonathan Kurtis, MD PhD.

Presentation will be hosted live on Ocean Biomedical’s Youtube Channel at 2:00pm ET Providence, RI, Sept. 14...

Form 8-K - Current report

Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S.

Ocean’s small molecule candidate significantly controls fibrosis progression in idiopathic pulmonary fibrosis...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple Cancers

Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack...

Ocean Biomedical (NASDAQ: OCEA) Share Price Target Now Averaging $18.21, Based on Research and Development Progress in Three Promising Programs Generating Novel Treatment Candidates for Cancer, Malaria, and Fibrosis.

Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack...

Form DEF 14A - Other definitive proxy statements

Form 424B3 - Prospectus [Rule 424(b)(3)]

Ocean Biomedical, Inc. (NASDAQ: OCEA) Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day

Ocean Biomedical’s Oncology Platform currently consists of 27 Patents Issued or Pending. Ocean Biomedical’s...